Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
In Reply.—Dr Lawyer's assertions, while interesting, are highly speculative and not supported by available pharmacological and clinical data. Lawyer cited 3 specific adverse experiences of concern: fever, influenza, and abdominal pain. These adverse experiences actually occurred at similar frequencies between treatment groups in our study (differences between treatment groups were not statistically significant based on the Fisher exact test). Furthermore, there is no evidence from the pediatric and adult montelukast clinical trials to date to indicate that infection occurs at a higher incidence or that abdominal pain occurs at a lower incidence with montelukast therapy than with placebo.
Knorr B, Reiss TF. Montelukast for Children With Asthma—Reply. JAMA. 1998;280(11):967. doi:10-1001/pubs.JAMA-ISSN-0098-7484-280-11-jbk0916